Archon Biosciences

Archon Biosciences is an early-stage biotech company pioneering a novel class of biologics known as Antibody Cages (AbCs), which are computationally designed to integrate antibody specificity with engineered protein structures for precise biodistribution and target engagement. The company's platform, rooted in Nobel Prize-winning computational protein design from the Baker Lab, enables the creation of molecules with tunable properties like agonism and antagonism to address previously intractable drug targets. Archon emerged from stealth in late 2024 with a focus on advancing its platform and pipeline through preclinical development, supported by a team of experienced founders and investors.

Antibody Cage (AbC) platform integrating antibody binding domains with computationally designed protein scaffolds for geometric control over valency, size, shape, and rigidity to tune biodistribution and function.

Archon operates in the emerging field of computational protein design therapeutics, competing with other startups and research spin-outs leveraging AI for novel biologic design. Its direct differentiation lies in its specific focus on geometrically engineering antibody constructs, competing against both conventional antibody developers and other novel protein scaffold technologies.